Genomictree

Genomictree FCF per Share

The Free Cash Flow per Share of Genomictree (228760.KQ) as of Nov 3, 2026 is -527.52 KRW. In the previous year, Free Cash Flow per Share was -674.68 KRW — a change of -21.81% (higher).

FCF per Share

-527.52KRW

YoY

-21.81%

Last updated:

Free Cash Flow per Share of Genomictree is 2025 -527.52 KRW. Free Cash Flow per Share of Genomictree was 2024 -674.68 KRW. It decreases by -21.81% higher compared to the previous year.

The Genomictree FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-333.80 KRW
Jan 1, 2019
-769.88 KRW
Jan 1, 2020
-643.97 KRW
Jan 1, 2021
-957.25 KRW
Jan 1, 2022
119.23 KRW
Jan 1, 2023
-472.62 KRW
Jan 1, 2024
-674.68 KRW
Jan 1, 2025
-527.52 KRW
The Genomictree FCF per Share history
YEARFCF per ShareYoY
-527.52KRW-21.81%
-674.68KRW+42.75%
-472.62KRW-496.41%
119.23KRW-112.45%
-957.25KRW+48.65%
-643.97KRW-16.35%
-769.88KRW+130.64%
-333.80KRW+87.98%
-177.57KRW+148.54%
-71.45KRW-22.41%
-92.08KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomictree Stock analysis

What does Genomictree do? Genomictree, Inc. generates revenue by developing and supplying diagnostic products focused on cancer screening and prognosis. The firm conducts genomic analysis using microarrays and next generation sequencing analysis, while also performing clinical trials for its molecular diagnostic products. These offerings are designed to support medical professionals in identifying and managing various oncological conditions through advanced genetic testing methodologies. The company’s product portfolio is divided into cancer molecular diagnostic products and molecular genetic diagnostic products. The cancer molecular diagnostic segment includes specific tests for colorectal cancer, bladder cancer, lung cancer, stomach cancer, and cervical cancer. This targeted approach allows the firm to address a broad spectrum of oncological needs within the diagnostic market. Within the molecular genetic diagnostic products category, Genomictree, Inc. provides epidermal growth factor receptor (EGFR) mutation diagnosis and human papilloma virus (HPV) diagnostic products. By offering these specialized genetic tests, the company serves the healthcare sector with tools necessary for precise patient diagnosis and treatment planning based on genomic data. Genomictree is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomictree stock

Free Cash Flow per Share of Genomictree is -527.52 KRW in 2025.

Free Cash Flow per Share of Genomictree changed from -674.68 KRW to -527.52 KRW, representing a -21.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Genomictree since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genomictree

All Key Metrics — Genomictree